A FLEXIBLE APPROACH TO NEUROPHARMACOLOGY

PROFOUND EXPERTISE IN NEUROSCIENCE AND TWO DECADES of experience enables QPS to offer a sophisticated range of validated transgenic and non-transgenic *in vivo* and *in vitro* models to profile new chemical or biological compounds in depth.



QPS NEUROPHARMACOLOGY OVERVIEW

The QPS preclinical Neuropharmacology group covers various validated transgenic and non-transgenic *in vivo* and *in vitro* models for neurodegeneration such as Alzheimer's Disease, Parkinson's Disease, for rare diseases including Huntington's Disease and ALS, for lipid storage disease and dyslipidemia, and for diseases like psychosis, anxiety, schizophrenia, or autism.

Transgenic and Non-transgenic Models

In vivo and *in vitro* models

AD, PD and Rare Diseases

Lysosomal Storage Diseases

PROFOUND EXPERTISE

The QPS Neuropharmacology Team is comprised of professionals with industry and academia expertise in custom development and validation of transgenic and non-transgenic *in vivo* and *in vitro* models, providing top-of-the-line services tailored to the specific needs of our clients.

Our neuropharmacologists have profound expertise and extensive hands-on experience of sophisticated projects that have addressed many new and already established drug targets in neurodegenerative diseases.

NEURODEGENERATIVE DISEASES

There has been a tremendous burst of information about cognition and its neuronal bases during the past two decades. As new knowledge develops, there is a need to continually update the preclinical and clinical pharmacological tools that we use to assess cognition and other brain functions. Keeping those tools updated is essential for evolving an in-depth understanding of the cognitive and/or motor deficits caused by neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's disease.



THE QPS NEUROSCIENCES TEAM

The QPS Neurosciences Team is familiar with the numerous treatment approaches developed for neurodegenerative diseases, and has conducted research on new drugs of every pharmacological class. Furthermore, our ADME experts have been using “drugability” screens for lead optimization to ensure higher technical success rates in selecting useful drug candidates.

At QPS we have a long track record of conducting clinical trials for numerous neurological and psychiatric disease therapies. Our clinicians are aware of the latest diagnostic criteria and the most recent developments in study design to fulfill the requirements of modern CNS research. They recognize the problems and limitations of currently available cognitive tests and are active in developing and validating new methodologies in close collaboration with key international opinion leaders. Their expertise includes complex study design with sequential CSF sampling, structural MRI, and PET.

QPS Neurosciences Team supports the quantification of all relevant disease biomarkers with state-of-the-art technologies. We are also involved in developing and standardizing new biomarkers to support early diagnosis and to document precise drug effects on important disease mechanisms.

SCIENTIFIC LEADERSHIP AND PROVEN RESULTS

Our dedicated, experienced team ensures that neuropharmacology studies meet all timelines and regulatory requirements.

- Animal Facility
- *In Vivo* Research Facility
- Cell Culture Laboratory
- Biochemistry Laboratory
- Histology Laboratory

QPS
CUSTOM-BUILT RESEARCH™

QPS IS A GLOBAL CRO WITH LOCATIONS AROUND THE WORLD

BENEFIT FROM THE WORLDWIDE RESOURCES THAT A GLOBAL CONTRACT RESEARCH ORGANIZATION BRINGS

Whether your focus is small molecules, protein biotherapeutics, vaccines, gene therapy or cell therapy, QPS provides a full range of bioanalytical services to support all of drug development needs from discovery, through clinical development and regulatory filing.

QPS
CUSTOM-BUILT RESEARCH™

TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT.
CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY!

Call +1 512 350 2827 Email infobd@qps.com